StockNews.AI
IONS
StockNews.AI
34 days

Ionis to hold second quarter 2025 financial results webcast

1. Ionis Pharmaceuticals will host a Q2 2025 financial results webcast. 2. The webcast is scheduled for July 30 at 11:30 a.m. Eastern Time. 3. Ionis has six marketed medicines and a strong pipeline. 4. They focus on neurology, cardiology, and RNA-targeted therapies. 5. The event may impact investor sentiment and trading activity.

Earnings
+1.05%Current Return
VS
+0.86%S&P 500
$4207/16 07:28 AM EDTEvent Start
$42.4407/17 02:02 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Webcasts often signal company transparency and engagement with investors, potentially driving positive market sentiment.

How important is it?

Upcoming financial results and company developments directly influence investor perceptions and stock performance.

Why Short Term?

Immediate impact expected from investor reactions to financial results and updates on programs.

Related Companies

BIIBVRTX
-Webcast scheduled for Wednesday, July 30 at 11:30 a.m. Eastern Time CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, July 30th at 11:30 a.m. Eastern Time to discuss its second quarter 2025 financial results and progress on key programs. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram. More News From Ionis Pharmaceuticals, Inc.

Related News